Identity
- Security key
- 11277
- Ticker
- ACTU
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2024-08-13
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ACTU
Detail
Enriched 2026-08-14 20:47
- Market cap
- $23,205,683.85
- Shares outstanding (class)
- 23,925,852
- Shares outstanding (weighted)
- 23,925,852
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 12
- Location
- FORT WORTH, TX
- Description
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Market cap and share counts drift.